

Supporting Information

Efficient Access to 1*H*-Indazoles via Copper-Catalyzed Cross-Coupling/Cyclization of 2-Bromoaryl Oxime Acetates and Amines

Xiaodong Tang, Hanling Gao, Jidan Yang, Wanqing Wu, Huanfeng Jiang*

School of Chemistry and Chemical Engineering, South China University of Technology,
Guangzhou 510640, China

E-mail: jianghf@scut.edu.cn; Fax and Tel.: (+86) 20-87112906


Table of Contents

General Information.....	[2]
General Procedure for the Synthesis of 1 <i>H</i> -Indazoles	[2]
Characterization Data for Compounds 3a-3y	[2]
References.....	[10]
NMR Spectra for Compounds 3a-3y	[11]

General Information


^1H and ^{13}C NMR spectra were recorded on BRUKER DRX-400 spectrometer using CDCl_3 as solvent and TMS as an internal standard. Gas chromatograph mass spectra were obtained with a SHIMADZU model GCMS-QP5000 spectrometer. High-resolution mass spectra (ESI) were obtained with a LCMS-IT-TOF mass spectrometer. Unless otherwise stated, all reagents and solvents were purchased from commercial suppliers and used without further purification. Oxime acetates were synthesized according to the literature procedure.¹

General Procedure for the Synthesis of 1*H*-Indazoles




The mixture of oxime acetates **1** (0.5 mmol), amines **2** (0.6 mmol), CuCl (10 mol %) and K_2CO_3 (1.0 mmol) in a 25 mL Schlenk tube was stirred in DMSO (2.0 mL) at 120 $^\circ\text{C}$, under N_2 for 6 h. When the reaction was completed (detected by TLC), the mixture was cooled to room temperature. The reaction was quenched with H_2O (10 mL) and extracted with EtOAc (3×10 mL) or CH_2Cl_2 (3×10 mL). The combined organic layers were dried over anhydrous Na_2SO_4 and then evaporated in vacuum. The residue was purified by column chromatography on silica gel to afford the corresponding pyrroles **3** with hexanes/ethyl acetate as the eluent.

Analysis Data for Compounds 3a-3y




3-methyl-1-phenyl-1*H*-indazole (**3a**)²

Yellow oil (89 mg, 86 %). ^1H NMR (400 MHz, CDCl_3) δ 7.74 – 7.71 (m, 4H), 7.54 – 7.50 (m, 2H), 7.44 – 7.40 (m, 1H), 7.32 (dd, $J = 14.6, 7.3$ Hz, 1H), 7.21 (t, $J = 7.5$ Hz, 1H), 2.67 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 144.0, 140.3, 139.5, 129.4, 127.2, 126.1, 124.9, 122.4, 120.8, 120.6, 110.4, 11.9. MS (EI, 70 eV) m/z : 208 (M^+), 193, 167, 139, 104, 77. IR (KBr): 1594, 1507, 1443, 750 cm^{-1} .




1-(4-methoxyphenyl)-3-methyl-1H-indazole (3b)²


Red oil (107 mg, 90 %). ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 8.1 Hz, 1H), 7.61 – 7.58 (m, 3H), 7.41 – 7.36 (m, 1H), 7.21 – 7.17 (m, 1H), 7.05 – 7.02 (m, 2H), 3.87 (s, 3H), 2.66 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.1, 143.4, 139.8, 133.5, 126.9, 124.5, 124.3, 120.5, 120.5, 114.6, 110.1, 55.6, 11.9. MS (EI, 70 eV) *m/z* : 238 (M⁺), 223, 195, 167, 154, 128, 92, 77. IR (KBr): 1604, 1517, 1447, 1249, 744 cm⁻¹.

**1-(4-fluorophenyl)-3-methyl-1H-indazole (3c)²**

Red oil (103 mg, 91 %). ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, *J* = 8.1 Hz, 1H), 7.69 – 7.61 (m, 3H), 7.44 – 7.40 (m, 1H), 7.23 – 7.19 (m, 3H), 2.66 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 160.9 (d, *J* = 244.2 Hz), 144.1, 139.6, 136.5 (d, *J* = 2.5 Hz), 127.3, 124.8, 123.2, 124.2 (d, *J* = 8.3 Hz), 120.8 (d, *J* = 18.9 Hz), 116.3, 116.1, 110.0, 11.9. MS (EI, 70 eV) *m/z* : 226 (M⁺), 184, 157, 131, 95, 75. IR (KBr): 1603, 1516, 1442, 1222, 747 cm⁻¹.


**1-(4-chlorophenyl)-3-methyl-1H-indazole (3d)²**

Yellow solid (100 mg, 83 %), m.p. = 91 – 92 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, *J* = 8.0 Hz, 1H), 7.68 – 7.65 (m, 3H), 7.50 – 7.41 (m, 3H), 7.22 (t, *J* = 7.4 Hz, 1H), 2.65 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 144.5, 139.4, 138.9, 131.4, 129.5, 127.4, 125.1, 123.3, 121.1, 120.8, 110.1, 11.9. MS (EI, 70 eV) *m/z* : 242 (M⁺), 206, 192, 166, 140, 111, 103, 75. IR (KBr): 1598, 1502, 1434, 1085, 747 cm⁻¹.

**1-(4-bromophenyl)-3-methyl-1H-indazole (3e)**


Yellow solid (120 mg, 84 %), m.p. = 89 – 90 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 8.0 Hz, 1H), 7.67 (d, *J* = 8.5 Hz, 1H), 7.64 – 7.59 (m, 4H), 7.44 (dd, *J* = 11.4, 4.0 Hz, 1H), 7.22 (t, *J* = 7.3 Hz, 1H), 2.65 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 144.6, 139.4, 139.3, 132.5, 127.5, 125.2,

123.7, 121.1, 120.8, 119.1, 110.2, 11.9. MS (EI, 70 eV) m/z : 286 (M^+), 206, 166, 139, 103, 76. HRMS-ESI (m/z): calcd for $C_{14}H_{12}BrN_2$, $[M+H]^+$: 287.0178; found, 287.0172. IR (KBr): 1591, 1492, 1019, 822, 745 cm^{-1} .




3-methyl-1-(4-nitrophenyl)-1H-indazole (3f)²

Yellow solid (109 mg, 86 %), m.p. = 144 – 145 °C. 1H NMR (400 MHz, $CDCl_3$) δ 8.40 – 8.37 (m, 2H), 7.95 (t, J = 6.0 Hz, 2H), 7.82 (d, J = 8.5 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.54 – 7.50 (m, 1H), 7.30 (t, J = 7.5 Hz, 1H), 2.66 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 146.7, 145.6, 144.5, 139.3, 128.2, 126.2, 125.3, 122.2, 121.2, 120.6, 110.6, 12.0. MS (EI, 70 eV) m/z : 253 (M^+), 223, 205, 192, 166, 140, 102, 76. IR (KBr): 1590, 1506, 1328, 845, 745 cm^{-1} .



3-methyl-1-(4-(methylsulfonyl)phenyl)-1H-indazole (3g)


Yellow solid (116 mg, 81 %), m.p. = 122 – 123 °C. 1H NMR (400 MHz, $CDCl_3$) δ 8.04 (d, J = 8.7 Hz, 2H), 7.95 – 7.92 (m, 2H), 7.76 (d, J = 8.5 Hz, 1H), 7.72 – 7.70 (m, 1H), 7.48 – 7.44 (m, 1H), 7.24 – 7.22 (m, 1H), 3.07 (s, 3H), 2.61 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 146.2, 144.8, 139.2, 136.6, 129.0, 128.1, 126.0, 121.9, 121.3, 121.1, 110.5, 44.7, 12.0. MS (EI, 70 eV) m/z : 286 (M^+), 223, 207, 192, 166, 139, 128, 102, 76. HRMS-ESI (m/z): calcd for $C_{15}H_{15}N_2O_2S$, $[M+H]^+$: 287.0849; found, 287.0852. IR (KBr): 1587, 1510, 1439, 1146, 756 cm^{-1} .



5-(4-(3-methyl-1H-indazol-1-yl)phenyl)oxazole (3h)


Yellow oil (100 mg, 73 %). 1H NMR (400 MHz, $CDCl_3$) δ 7.95 (s, 1H), 7.80 (s, 4H), 7.76 – 7.73 (m, 2H), 7.47 – 7.40 (m, 2H), 7.23 (d, J = 7.8 Hz, 1H), 2.67 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 151.1, 150.5, 144.7, 140.5, 139.3, 127.5, 125.9, 125.3, 125.2, 122.3, 121.5, 121.2, 120.8, 110.4, 12.0. MS (EI, 70 eV) m/z : 275 (M^+), 246, 219, 205, 178, 137, 110, 89, 76. HRMS-ESI (m/z): calcd for $C_{17}H_{14}N_3O$, $[M+H]^+$: 276.1131; found, 276.1130. IR (KBr): 1597, 1513, 1438, 1021,

750 cm⁻¹.




1-(4-(1H-pyrrol-1-yl)phenyl)-3-methyl-1H-indazole (3i)

Red solid (105 mg, 77 %), m.p. = 104 – 105 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.77 – 7.68 (m, 4H), 7.51 (d, *J* = 8.8 Hz, 2H), 7.43 (t, *J* = 7.7 Hz, 1H), 7.20 (dd, *J* = 14.3, 7.0 Hz, 1H), 7.13 – 7.10 (m, 2H), 6.38 – 6.37 (m, 2H), 2.66 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 144.3, 139.5, 138.6, 137.9, 127.3, 125.0, 123.3, 121.3, 121.0, 120.8, 119.4, 110.7, 110.2, 12.0. MS (EI, 70 eV) *m/z*: 273 (M⁺), 231, 204, 182, 154, 115, 102, 89, 76. HRMS-ESI (*m/z*): calcd for C₁₈H₁₆N₃, [M+H]⁺: 274.1339; found, 274.1337. IR (KBr): 1517, 1457, 1325, 1022, 829, 733 cm⁻¹.




1-(4-(1H-pyrazol-1-yl)phenyl)-3-methyl-1H-indazole (3j)

Yellow oil (104 mg, 76 %). ¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, *J* = 2.3 Hz, 1H), 7.86 – 7.80 (m, 4H), 7.76 – 7.70 (m, 3H), 7.44 (t, *J* = 7.8 Hz, 1H), 7.23 (t, *J* = 7.6 Hz, 1H), 6.50 (t, *J* = 2.0 Hz, 1H), 2.67 (s, 3H). ¹³C NMR (100MHz, CDCl₃) δ 144.4, 141.3, 139.5, 138.6, 138.0, 127.4, 126.8, 125.1, 123.1, 121.0, 120.8, 120.1, 110.2, 107.8, 12.0. MS (EI, 70 eV) *m/z* : 274 (M⁺), 246, 205, 195, 137, 103, 89, 76. HRMS-ESI (*m/z*): calcd for C₁₇H₁₅N₄, [M+H]⁺: 275.1291; found, 275.1289. IR (KBr): 1581, 1526, 1444, 1393, 838, 747 cm⁻¹.




1-(2-methoxyphenyl)-3-methyl-1H-indazole (3k)²

Brown oil (90 mg, 76 %). ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, *J* = 8.1 Hz, 1H), 7.47 – 7.34 (m, 3H), 7.21 – 7.16 (m, 2H), 7.09 (d, *J* = 8.0 Hz, 2H), 3.79 (s, 3H), 2.67 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 154.2, 143.6, 141.3, 129.2, 128.6, 128.5, 126.5, 123.8, 121.0, 120.2, 120.2, 112.3, 111.0, 55.8, 12.0. MS (EI, 70 eV) *m/z*: 238 (M⁺), 221, 207, 196, 167, 143, 119, 77. IR (KBr): 1593, 1513, 1461, 1251, 750 cm⁻¹.




1-(3-methoxyphenyl)-3-methyl-1H-indazole (3l)²

Red oil (84 mg, 71 %). ¹H NMR (400 MHz, CDCl₃) δ 7.75 – 7.68 (m, 2H), 7.44 – 7.39 (m, 2H), 7.31 – 7.28 (m, 2H), 7.21 (t, *J* = 7.6 Hz, 1H), 6.87 (dd, *J* = 8.2, 1.7 Hz, 1H), 3.89 (s, 3H), 2.66 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.5, 144.0, 141.4, 139.5, 130.1, 127.2, 125.1, 120.9, 120.6, 114.5, 112.1, 110.5, 108.1, 55.9, 12.3. MS (EI, 70 eV) *m/z*: 238 (M⁺), 208, 167, 154, 127, 92, 77. IR (KBr): 1598, 1495, 1348, 844, 745 cm⁻¹.




1-(2,6-dimethylphenyl)-3-methyl-1H-indazole (3m)

Brown oil (106 mg, 90 %). ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, *J* = 8.1 Hz, 1H), 7.34 – 7.25 (m, 2H), 7.18 – 7.14 (m, 3H), 6.94 (dd, *J* = 22.0, 11.5 Hz, 1H), 2.67 (s, 3H), 1.92 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 142.8, 141.0, 137.5, 137.1, 129.0, 128.3, 126.7, 123.1, 120.4, 120.0, 109.5, 17.5, 12.1. MS (EI, 70 eV) *m/z* : 236 (M⁺), 221, 194, 180, 117, 103, 77. HRMS-ESI (*m/z*): calcd for C₁₆H₁₇N₂, [M+H]⁺ : 237.1386; found, 237.1381. IR (KBr): 1580, 1507, 1352, 1025, 751 cm⁻¹.




1-mesityl-3-methyl-1H-indazole (3n)

Red oil (105 mg, 84 %). ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, *J* = 8.1 Hz, 1H), 7.32 (t, *J* = 7.6 Hz, 1H), 7.16 (t, *J* = 7.4 Hz, 1H), 6.99 – 6.97 (m, 3H), 2.67 (s, 3H), 2.37 (s, 3H), 1.89 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 142.6, 141.2, 138.7, 137.1, 134.5, 129.0, 126.6, 123.1, 120.3, 119.9, 109.6, 21.2, 17.4, 12.1. MS (EI, 70 eV) *m/z*: 250 (M⁺), 235, 208, 194, 117, 91, 77. HRMS-ESI (*m/z*): calcd for C₁₇H₁₉N₂, [M+H]⁺ : 251.1543; found, 251.1539. IR (KBr): 1586, 1509, 1349, 1022, 747 cm⁻¹.




3-methyl-1-(naphthalen-1-yl)-1H-indazole (3o)


Red oil (101 mg, 78 %). ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J* = 8.0 Hz, 2H), 7.78 (d, *J* = 8.0 Hz, 1H), 7.65 – 7.50 (m, 4H), 7.42 (dd, *J* = 13.9, 6.7 Hz, 1H), 7.34 – 7.28 (m, 1H), 7.24 – 7.16 (m, 2H), 2.72 (s, 3H). ¹³C NMR (100MHz, CDCl₃) δ 143.8, 142.1, 136.0, 134.6, 130.1, 128.8, 128.2, 126.9, 126.9, 126.6, 125.4, 124.6, 123.9, 123.7, 120.6, 120.4, 110.4, 12.1. MS (EI, 70 eV) *m/z* : 258 (M⁺), 241, 216, 189, 127, 107, 73. HRMS-ESI (*m/z*): calcd for C₁₈H₁₅N₂, [M+H]⁺ : 259.1230; found, 259.1229. IR (KBr): 1506, 1418, 1345, 1018, 751 cm⁻¹.

**3-methyl-1-(pyridin-2-yl)-1H-indazole (3p)³**


Yellow oil (89 mg, 85 %). ¹H NMR (400 MHz, CDCl₃) δ 8.78 (d, *J* = 8.5 Hz, 1H), 8.49 (t, *J* = 14.6 Hz, 1H), 7.99 (d, *J* = 8.4 Hz, 1H), 7.84 – 7.75 (m, 1H), 7.68 – 7.66 (m, 1H), 7.52 – 7.45 (m, 1H), 7.25 (t, *J* = 7.5 Hz, 1H), 7.09 – 7.06 (m, 1H), 2.64 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 154.3, 147.7, 145.6, 139.5, 138.1, 127.9, 125.8, 121.9, 120.0, 119.3, 115.3, 113.1, 12.1. MS (EI, 70 eV) *m/z* : 209 (M⁺), 194, 168, 140, 131, 78. IR (KBr): 1588, 1521, 1454, 1076, 755 cm⁻¹.

**3-methyl-1-(pyridin-3-yl)-1H-indazole (3q)**

Red oil (92 mg, 88 %). ¹H NMR (400 MHz, CDCl₃) δ 9.07 (s, 1H), 8.56 (d, *J* = 4.5 Hz, 1H), 8.06 (d, *J* = 8.2 Hz, 1H), 7.73 (t, *J* = 9.0 Hz, 2H), 7.49 – 7.44 (m, 2H), 7.26 (d, *J* = 5.6 Hz, 1H), 2.66 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 147.0, 145.4, 143.2, 139.5, 137.1, 129.2, 127.7, 125.3, 124.0, 121.4, 120.9, 110.0, 12.0. MS (EI, 70 eV) *m/z* : 209 (M⁺), 168, 140, 114, 77. HRMS-ESI (*m/z*): calcd for C₁₃H₁₂N₃, [M+H]⁺: 210.1026; found, 210.11026. IR (KBr): 1579, 1518, 1450, 1074, 750 cm⁻¹.


**3-methyl-1-(pyridin-4-yl)-1H-indazole (3r)**

Brown oil (100 mg, 96 %). ¹H NMR (400 MHz, CDCl₃) δ 8.74 (s, 2H), 7.86 (d, *J* = 8.5 Hz, 1H), 7.80 – 7.71 (m, 3H), 7.51 (t, *J* = 7.7 Hz, 1H), 7.32 – 7.26 (m, 1H), 2.64 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 150.8, 147.1, 146.5, 139.2, 128.2, 126.3, 122.1, 121.1, 110.9, 12.0. MS (EI, 70 eV) *m/z* : 209 (M⁺), 168, 140, 114, 77. HRMS-ESI (*m/z*): calcd for C₁₃H₁₂N₃, [M+H]⁺: 210.1026; found, 210.1027. IR (KBr): 1592, 1508, 1439, 1022, 749 cm⁻¹.




3-methyl-1-(pyrimidin-2-yl)-1H-indazole (3s)

Yellow solid (101 mg, 96 %). m.p. = 106 – 107 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.32 (s, 1H), 8.62 (d, *J* = 8.5 Hz, 1H), 8.32 (d, *J* = 17.0 Hz, 2H), 7.64 (d, *J* = 8.0 Hz, 1H), 7.47 (t, *J* = 7.8 Hz, 1H), 7.25 – 7.21 (m, 1H), 2.60 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 147.1, 141.3, 140.0, 139.0, 136.2, 128.3, 126.0, 122.7, 120.2, 115.0, 12.1. MS (EI, 70 eV) *m/z*: 210 (M⁺), 195, 169, 142, 131, 102, 77. HRMS-ESI (*m/z*): calcd for C₁₂H₁₁N₄, [M+H]⁺: 211.0978; found, 211.0974. IR (KBr): 1579, 1529, 1448, 1018, 751 cm⁻¹.




3-methyl-1-(1-methyl-1H-pyrazol-3-yl)-1H-indazole (3t)

Red oil (99 mg, 93 %). ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.4 Hz, 1H), 7.68 (d, *J* = 8.0 Hz, 1H), 7.46 (t, *J* = 7.7 Hz, 1H), 7.37 (s, 1H), 7.20 (t, *J* = 7.4 Hz, 1H), 6.53 (s, 1H), 3.94 (s, 3H), 2.64 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 150.2, 144.2, 139.2, 131.0, 127.4, 124.5, 121.0, 120.1, 112.5, 96.3, 39.2, 12.0. MS (EI, 70 eV) *m/z*: 212 (M⁺), 170, 131, 102, 77. HRMS-ESI (*m/z*): calcd for C₁₂H₁₃N₄, [M+H]⁺: 213.1135; found, 213.1124. IR (KBr): 1581, 1526, 1445, 1028, 750 cm⁻¹.



3-methyl-1-propyl-1H-indazole (3u)


Red oil (57 mg, 65 %). ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, *J* = 8.1 Hz, 1H), 7.36 (d, *J* = 12.8 Hz, 2H), 7.15 – 7.02 (m, 1H), 4.27 (t, *J* = 7.0 Hz, 2H), 2.58 (s, 3H), 1.98 – 1.87 (m, 2H), 0.93 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 141.1, 140.4, 126.0, 123.2, 120.4, 119.5, 108.9, 50.2, 23.4, 11.9, 11.5. MS (EI, 70 eV) *m/z*: 174 (M⁺), 145, 128, 91, 77. HRMS-ESI (*m/z*): calcd for C₁₁H₁₅N₂, [M+H]⁺: 175.1230; found, 175.1224. IR (KBr): 1583, 1473, 1349, 1027, 747 cm⁻¹.



1-(cyclopropylsulfonyl)-3-methyl-1H-indazole (3v)


Red oil (96 mg, 81 %). ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, *J* = 8.4 Hz, 1H), 7.68 (d, *J* = 8.0 Hz,

1H), 7.52 (t, $J = 7.7$ Hz, 1H), 7.34 (t, $J = 7.5$ Hz, 1H), 2.69 – 2.65 (m, 1H), 2.61 (s, 3H), 1.42 – 1.41 (m, 2H), 1.01 – 0.98 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 150.1, 141.3, 129.1, 125.8, 123.7, 120.6, 113.1, 31.0, 12.3, 6.1. MS (EI, 70 eV) m/z : 236 (M^+), 171, 157, 145, 132, 103, 77. HRMS-ESI (m/z): calcd for $\text{C}_{11}\text{H}_{13}\text{N}_2\text{O}_2\text{S}$, $[\text{M}+\text{H}]^+$: 237.0692; found, 237.0696. IR (KBr): 1618, 1520, 1440, 1368, 1169, 755 cm^{-1} .




3-methyl-1-(phenylsulfonyl)-1H-indazole (3w)

Red oil (120 mg, 88 %). ^1H NMR (400 MHz, CDCl_3) δ 8.17 (d, $J = 8.4$ Hz, 1H), 7.95 (d, $J = 7.7$ Hz, 2H), 7.59 (d, $J = 7.9$ Hz, 1H), 7.57 – 7.53 (m, 2H), 7.43 (t, $J = 7.5$ Hz, 2H), 7.32 (t, $J = 7.5$ Hz, 1H), 2.52 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 150.9, 141.1, 137.7, 133.9, 129.2, 129.1, 127.4, 126.2, 124.0, 120.6, 113.4, 12.3. MS (EI, 70 eV) m/z : 272 (M^+), 253, 218, 208, 141, 131, 103, 77. HRMS-ESI (m/z): calcd for $\text{C}_{14}\text{H}_{13}\text{N}_2\text{O}_2\text{S}$, $[\text{M}+\text{H}]^+$: 273.0692; found, 273.0699. IR (KBr): 1585, 1443, 1373, 1250, 1180, 757 cm^{-1} .



5-fluoro-3-methyl-1-phenyl-1H-indazole (3x)

Yellow oil (90 mg, 80 %). ^1H NMR (400 MHz, CDCl_3) δ 7.70 – 7.61 (m, 3H), 7.52 (t, $J = 7.6$ Hz, 2H), 7.33 (t, $J = 7.1$ Hz, 2H), 7.18 (t, $J = 8.9$ Hz, 1H), 2.62 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.5 (d, $J = 223\text{Hz}$), 143.6, 140.1, 136.5, 129.5, 126.4, 125.1 (d, $J = 9.5\text{Hz}$), 122.3, 116.4 (d, $J = 26.9\text{Hz}$), 111.5 (d, $J = 9.2\text{Hz}$), 104.8, (d, $J = 23.1\text{Hz}$), 11.9. MS (EI, 70 eV) m/z : 226 (M^+), 221, 184, 158, 113, 77. HRMS-ESI (m/z): calcd for $\text{C}_{14}\text{H}_{12}\text{FN}_2$, $[\text{M}+\text{H}]^+$: 227.0979; found, 227.0970. IR (KBr): 1594, 1445, 1026, 748 cm^{-1} .



6-fluoro-3-methyl-1-phenyl-1H-indazole (3y)

Red oil (89 mg, 79 %). ^1H NMR (400 MHz, CDCl_3) δ 7.67 – 7.63 (m, 3H), 7.54 – 7.50 (m, 2H), 7.35 – 7.33 (m, 2H), 6.99 – 6.95 (m, 1H), 2.63 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 162.9 (d, $J = 243.6\text{Hz}$), 144.2, 139.9, 139.8 (d, $J = 12.5\text{Hz}$), 129.51, 126.5, 122.3, 122.0 (d, $J = 11.1\text{Hz}$), 121.8, 110.5 (d, $J = 25.8\text{Hz}$), 96.34 (d, $J = 27.2\text{Hz}$), 11.9. MS (EI, 70 eV) m/z : 226 (M^+), 221, 185, 157, 149, 77. HRMS-ESI (m/z): calcd for $\text{C}_{14}\text{H}_{12}\text{FN}_2$, $[\text{M}+\text{H}]^+$: 227.0979; found, 227.0972. IR (KBr):


1587, 1504, 1428, 1028, 757 cm⁻¹.


References

1. P. C. Too, Y-F. Wang, S. Chiba, *Org. Lett.* 2010, **12**, 5688.
2. B. C. Wray, J. P. Stambuli, *Org. Lett.* 2010, **12**, 4576.
3. X. D. Xiong, Y. W. Jiang, D. W. Ma, *Org. Lett.* 2012, **14**, 2552.


NMR Spectra for Compounds 3a-3y


3a







3b







3c







3d







3e







3f







3g







3h







3i







3j







3k







3l







3m







3n







3o







3p







3q







3r







3s







3t







3u







3v







3w





3x





3y

